< Back to latest news & events

Blogs

AI-Powered Personalised Medicine

September 2023

The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt a one-size-fits-all model, but AI-powered personalised medicine is changing the game by harnessing the power of data, machine learning (ML), and advanced analytics to create individualised healthcare plans.  

Personalised medicine or healthcare, also known as precision medicine, is an approach to healthcare that customises medical decisions, practices, and products to the individual patient. The goal is to provide treatments that are more effective, minimise side effects, and optimise outcomes based on each patient’s unique genetic makeup, medical history, and lifestyle. 

AI plays a pivotal role in personalised medicine by processing vast amounts of patient data, identifying patterns, and generating insights that aid in diagnosis, treatment selection, and prognosis. Here’s a few examples of how AI is revolutionising personalised medicine: 

Data Analysis and Integration: AI algorithms excel at processing and integrating diverse data types, including genetic information, medical records, imaging, and wearable device data. This comprehensive view of a patient’s health allows for a more accurate and holistic assessment. 

Genomic Medicine: AI is instrumental in analysing an individual’s genetic makeup. By identifying specific genetic markers and mutations, AI can predict disease susceptibility, select targeted therapies, and even predict the likelihood of treatment success. 

Drug Discovery and Development: AI accelerates drug discovery by sifting through vast chemical libraries, predicting potential drug candidates, and assessing their safety and efficacy. This approach streamlines the development process, reducing costs and timelines. 

Treatment Personalisation: AI can analyse patient data to identify the most suitable treatment options, including drug dosages and therapy regimens. This ensures that treatments are tailored to an individual’s unique needs, improving both effectiveness and patient compliance. 

Disease Prediction and Prevention: AI models can predict disease onset by analysing patient data and recognising early warning signs. This allows for proactive interventions, lifestyle adjustments, and preventive measures. 

Real-Time Monitoring: Wearable devices and sensors equipped with AI algorithms enable continuous health monitoring. These devices can detect abnormalities and alert healthcare providers and patients, enabling timely intervention. 

These are examples of AI in personalised medicine. However, AI is also progressing innovation in healthcare more broadly too, as demonstrated by the Food and Drug Administration (FDA) in the US which has put together a list of AI/ML medical algorithms that are cleared for the market. So far, there are over 500 that have been cleared and the majority of these relate to medical imaging, for example, in diagnostics [1].  

The Medicines and Healthcare Products Regulatory Agency (MHRA) has not published a similar list; however the UK government recognises the importance of AI’s role in future healthcare and announced in March 2023 that they are funding nine of the most promising AI healthcare technologies to accelerate research [2]. Similarly, in August 2023, the UK Government announced 22 projects that will receive funding to explore how to develop and use AI in healthcare. One of these projects (University of Oxford) relates to personalised healthcare where AI is used for clinical risk prediction to determine the likelihood of future health problems based on an individual’s existing conditions.  The UK Government have also appointed two leading experts to take the lead on UK hosting the first major international summit on safe use of AI, Autumn 2023. [3]  

The progression of medical technology in general is also reflected in the number of patent filings where medical technology was one of the main drivers of growth in patent filings at the EPO in 2022. Looking at the number of AI patent applications published by the EPO, this number has significantly increase over the last few years and in 2022 over 10 000 AI patent applications were published.  

AI-powered personalised medicine represents a shift in healthcare, moving away from one-size-fits-all approaches, towards tailored treatments and interventions. By harnessing the capabilities of AI to analyse vast datasets and extract meaningful insights, healthcare providers can offer more precise diagnoses, treatment plans, and preventive strategies. As research and technology continue to advance, AI-powered personalised medicine will continue to reshape the way we understand and approach healthcare. 

 

This article was prepared by HGF Patent Director Dr Sofie McPherson

 

[1]. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#resources 

[2]. https://www.gov.uk/government/news/thousands-of-patients-to-benefit-from-quicker-diagnosis-more-accurate-tests-from-ground-breaking-ai-research 

[3] https://www.gov.uk/government/news/experts-to-lead-ai-safety-summit-preparations-as-new-funding-announced-to-modernise-healthcare 

 

Latest updates

Agritech Thymes: Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article